Compare Devon Energy Corp (DVN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Mesoblast Limited — how do they compare? Devon Energy Corp trades at $42.58 (market cap $50.44B), while Mesoblast Limited trades at $18.12 (market cap $2.12B). The key difference: Devon Energy Corp is far larger — about 23.8× Mesoblast Limited's market cap, and Devon Energy Corp pays a 2.38% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DVN | MESO | |
|---|---|---|
Market Cap | $50.44B | $2.12B |
Sector | Energy | Technology |
52-Week High | $52.07 | $20.96 |
52-Week Low | $31.74 | $10.96 |
Enterprise Value | $57.22B | $2.13B |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $43.73, up 3.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q3 and Q4 2025 but missing in Q1 2026, with Q2 results pending. The company maintains solid profitability with a 13.71% net margin and robust cash flow, supported by the Coterra acquisition targeting $2 billion in synergies by 2027. Debt-to-asset ratio improved to 26.54% in 2025, reflecting disciplined financial management.
Outlook remains positive with a consensus price target of $60.55, implying significant upside. Key opportunities include synergy realization and free cash flow growth, while risks involve oil price volatility and activist investor pressure for asset sales. The stock offers value with a P/E of 12.18, below sector averages, but investors should monitor Q2 earnings due August 4 for confirmation of growth trajectory.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
